Skip to content
Screener

Fractyl Health GUTS Q3 2026 earnings

Reported November 12, 2026 · After market close

EPS-$1.07Beat by $0.43
EPS estimate-$1.50
“Armed with positive data, we have focused the Company around Revita's post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”
Harith Rajagopalan

Next report

Date not yet announced

FAQ

When did Fractyl Health report Q3 2026 earnings?
Fractyl Health (GUTS) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Fractyl Health's Q3 2026 revenue and EPS?
Fractyl Health reported eps of $-1.07 for Q3 2026.
Did Fractyl Health beat estimates in Q3 2026?
EPS beat the consensus estimate of $-1.50 by $0.43.
How did Fractyl Health's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 205.7% from $-0.35.
Where can I find Fractyl Health's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-458308) and the 10-Q periodic report (0001193125-26-458318) directly on SEC EDGAR. The filing index links above go to sec.gov.